

State Systems Development

Florida Advancing Recovery Implementing Medication Assisted Treatment

Presentation by

Stephenie W. Colston, M.A.

Director of Florida Substance Abuse Program

Florida Advancing Recovery Partnership

- Department of Children and Families
Substance Abuse Program Office
- Florida Alcohol and Drug Abuse Association
(FADAA)
- Provider Agencies:
 - Operation Par
 - River Region Human Services
 - Spectrum Programs

Why Medication Assisted Treatment ?

- Supports state strategic initiatives
- Impacts client outcomes
- Improves efficiency to system

Strategic Initiative

Increase consumer access to recovery and evidence based services and supports:

- Implement the Advancing Recovery Foundation grant to promote the use of evidence based practices.
- Increase recovery support.
- Establish linkages between detox and other services.

Potential to Impact Treatment Outcomes

- Florida provides substance abuse services to more than 140,000 individuals yearly.
- More than 34% of the adults admitted for treatment indicate their primary drug of choice is alcohol.

Potential to Impact Treatment Outcomes

- Nearly 24,000 persons are admitted for Detox services within a given year.
- More than 11,000 persons receiving substance abuse treatment services report problems with alcohol abuse.
 - Of that group, more than 4,000 have experienced multiple tx. Admissions.
 - More than 1,700 of these individuals have experienced more than two previous admissions.

Statewide Aim and Goal

Aim

- Increase client retention in substance abuse treatment through the use of Vivitrol for the treatment of alcoholism.

Goal/Direction

- Increase positive treatment outcomes through administering medication and appropriate psychosocial interventions.

Key Activities


- Training and education to staff and clients
- Identified Mechanism for funding – IDP
- Partnered with State Pharmacy
- Developed Budget Review and Transfer Process
- Obtaining Medication
- Identifying Agencies and target groups for further expansion
- Statewide Survey

Results


- Improved client outcomes
- Partnerships
- Infrastructure Development
- Established new processes
- Expansion Options

Average Number of Heavy Drinking Days per Month/Injection - Statewide

Three or More Consecutive Injections



Mean Number of Days Clients Receiving Vivitrol Who Remain in Program by Month of Admission



As of May 20, 2008

Developing Partnerships

- State Pharmacy
- Mental Health Program
- AHCA
- Local Communities

Infrastructure Development

- Identify Available Budget
- Develop Budget Tracking Codes
- Budget Review and Transfer Process
- Reimbursement Mechanisms

MAT Expansion

- Statewide Survey
 - Web-based
 - Sent to provider agencies across the state
 - Reminders
 - 44 responses to date

MAT Survey Results

- Types of Services Offered
 - 90% Outpatient
 - 55% Long-term Residential
 - 48% Inpatient Detoxification
 - 46% Short-term Residential
- Medication-Assisted Treatment
 - 52%

MAT Survey Results

Medication Offered	Number of Clients
Methadone	3,428
Buprenorphine	987
Naltrexone (for opiate & alcohol tx)	268
Acamprosate	377
Vivitrol	30
Other (Anabuse, Campral, Chantix)	15

MAT Survey

Capacity to Implement MAT

Type	Full-Time	Part-Time
Clinical Director	90%	7%
Medical Director	40%	51%
Pharmacy Director	27%	22%
Licensed Pharmacy	39%	11%
Psychiatrist	45%	11%
Nursing	77%	21%

MAT Survey Responses

- Interest by providers to expand or implement use of MAT
 - 89% Vivitrol & Buprenorphine
 - 86% Acamprosate & Naltrexone
 - 76% Methadone

Next Steps

- Spread and Dissemination
 - Increase number of agencies
 - Increase clients receiving MAT (medicaid eligible)
 - Increase types of medications offered
- Continue to evaluate client outcomes
 - Recidivism
 - Employment
- Develop Business Case
- Sustain Changes